argenx

argenx EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of argenx (ARGX.BR) as of Nov 17, 2026 is 40.29. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -231.93 — a change of -117.37% (higher).

EV/FCF

40.29

YoY

-117.37%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of argenx is 2025 40.29 . EV/FCF (Enterprise Value to Free Cash Flow) of argenx was 2024 -231.93 . It decreases by -117.37% higher compared to the previous year.

The argenx EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-604.90 USD
Jan 1, 2019
351.59 USD
Jan 1, 2020
-90.15 USD
Jan 1, 2021
-49.50 USD
Jan 1, 2022
-37.44 USD
Jan 1, 2023
-75.87 USD
Jan 1, 2024
-231.93 USD
Jan 1, 2025
40.29 USD
The argenx EV/FCF history
YEAREV/FCFYoY
40.29-117.37%
-231.93+205.71%
-75.87+102.63%
-37.44-24.36%
-49.50-45.09%
-90.15-125.64%
351.59-158.12%
-604.90-29.43%
-857.14-122.94%
3,737.05-251.12%
-2,472.85-57.45%
-5,811.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

argenx Stock analysis

What does argenx do? Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. The company was founded in 2008 and is headquartered in Gent, Belgium. Argenx utilizes an innovative technology platform, the Simple Antibody platform, to develop customized antibodies with high efficacy. Argenx operates in two main business areas: clinical development and licensing. The company aims to produce outstanding therapeutic agents from each of its platform technologies and drug candidates, which can be used as antibody therapies against serious autoimmune diseases or cancer. Argenx's main product is the drug Efgartigimod, a monoclonal antibody developed for the treatment of multiple autoimmune diseases, particularly generalized Myasthenia Gravis (GMG). The drug is currently in clinical development. In recent years, Argenx has made significant progress in the development of new drugs. For example, the company has announced the discovery of new antibodies for the treatment of Myasthenia Gravis, rheumatoid arthritis, and various types of cancer. Licensing these development pipelines opens up new opportunities for Argenx to create additional therapy options for patients with serious illnesses. Argenx has also established partnerships with leading pharmaceutical companies such as Shire and AbbVie to expand its technology platform and drug candidates into new areas of application. The company is currently working on the development of therapies for rare and serious diseases that have no satisfactory treatment options. With the advancement of its innovative technology platform and the expansion of its portfolio of drug candidates, Argenx is on a promising path to play a leading role in the industry. The company is building an extensive network of partnerships and collaborations to accelerate the further development of its technology platform and products, and to achieve further success in the search for new therapeutic applications and areas of application. Looking ahead, Argenx is poised to play a significant role in the biopharmaceutical industry, particularly in the development of personalized therapy options for the treatment of serious diseases where no satisfactory treatment options currently exist. Argenx is proud of its dedicated team of employees who strive every day to realize the company's vision - to help patients cope with serious illnesses through new and innovative therapies. Output: Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. argenx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about argenx stock

EV/FCF (Enterprise Value to Free Cash Flow) of argenx is 40.29 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of argenx changed from -231.93 to 40.29, representing a -117.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) argenx since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s argenx with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — argenx

All Key Metrics — argenx